MedPath

Tavotek Lab Inc

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:2
Completed:2

Trial Phases

2 Phases

Phase 1:4
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
4 (80.0%)
Phase 2
1 (20.0%)

A Study of TAVO412 in Patients with Cancer (TAVO412)

Phase 1
Recruiting
Conditions
Cancer
Interventions
First Posted Date
2025-01-07
Last Posted Date
2025-01-16
Lead Sponsor
Tavotek Biotherapeutics
Target Recruit Count
50
Registration Number
NCT06761651
Locations
πŸ‡¨πŸ‡³

Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China

πŸ‡¨πŸ‡³

First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

πŸ‡¨πŸ‡³

Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

and more 3 locations

A Study of TAVO101 in Atopic Dermatitis Patients

Phase 2
Active, not recruiting
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2023-12-19
Last Posted Date
2024-11-18
Lead Sponsor
Tavotek Biotherapeutics
Target Recruit Count
20
Registration Number
NCT06176040
Locations
πŸ‡¦πŸ‡Ί

Royal Melbourne Hospital, Parkville, Victoria, Australia

πŸ‡³πŸ‡Ώ

Optimal Clinical Trials, Auckland, New Zealand

A Study of TAVO412 in Patients with Cancer

Phase 1
Active, not recruiting
Conditions
Cancer
Interventions
First Posted Date
2022-09-21
Last Posted Date
2024-10-23
Lead Sponsor
Tavotek Biotherapeutics
Target Recruit Count
50
Registration Number
NCT05548634
Locations
πŸ‡ΊπŸ‡Έ

Tisch Cancer Center, NYC, New York, United States

Study of TAVO103A in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Other: Placebo
First Posted Date
2022-04-06
Last Posted Date
2023-12-12
Lead Sponsor
Tavotek Biotherapeutics
Target Recruit Count
30
Registration Number
NCT05313152
Locations
πŸ‡ΊπŸ‡Έ

ICON, Salt Lake City, Utah, United States

Study of TAVO101 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Subjects
First Posted Date
2022-03-28
Last Posted Date
2024-11-19
Lead Sponsor
Tavotek Biotherapeutics
Target Recruit Count
42
Registration Number
NCT05298046
Locations
πŸ‡¦πŸ‡Ί

CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.